Financial Times: New Alzheimer's drug a test for amyloid hypothesis
UC's Espay comments on lecanemab
Japanese company Eisai released preliminary trial data in September on experimental Alzheimer's drug lecanemab that showed it slowed the progression rate of the disease.
The drug is the latest in a series of drugs that stem from what's called the amyloid hypothesis that Alzheimer's is primarily caused by the build-up of amyloid plaques in the brain. Drugs like lecanemab aim to remove the plaques to slow the rate of decline.
The University of Cincinnati's Alberto Espay, MD, proposes an alternative theory that it is the loss of the normal amyloid protein, rather than the build-up of the abnormal amyloid plaques, that leads to degeneration.
Espay, professor of neurology in the UC College of Medicine, director and endowed chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders at the UC Gardner Neuroscience Institute and a UC Health physician, told the Financial Times that lecanemab increases levels of the normal protein in the brain in addition to removing plaques, which could be the cause of the benefits seen in the trial.
Read more about Espay's research and alternative hypothesis.
Read the Financial Times article. (Note: Account creation or subscription may be required to access article.)
Featured photo at top courtesy of Unsplash.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.